twiist + CGM: Meet a Dynamic Duo

See how twiist works with continuous glucose monitoring.

FreeStyle Libre 3 Plus sensor is indicated for use in people with diabetes age 2 and older. The twiist AID System is for people with type 1 diabetes, ages 6+.

twiist + CGM: Meet a Dynamic Duo

See how twiist works with continuous glucose monitoring.

For a seamless experience, twiist uses continuous glucose monitor (CGM) readings to adjust your insulin as needed.

FreeStyle Libre 3 Plus sensor

Eversense 365

The twiist AID System uses your CGM's measurements, personalized settings, and predicted glucose levels to adjust your insulin to help prevent highs and lows.

twiist also uses iiSure™ Technology to provide accurate insulin delivery and reliability with advanced occlusion (blockage) detection.

FreeStyle Libre 3 Plus sensor is an easy to wear¹², accurate¹³, and affordable^§14 CGM—and the world's smallest^¶14 15-day sensor.

The sensor is applied painlessly¹² to the back of your upper arm and streams glucose readings minute-by-minute to twiist so you can know your glucose anytime^# with a quick glance.

A great combination that works for you

Predictive and adaptive insulin delivery
Small and discreet system
twiist is compatible with iPhone and Apple Watch
Single-app set up
No sensor coding required
Personalized support when you need it
Simplified diabetes management

Watch the Video

twiist will be the first AID system compatible with Eversense® 365This collaboration represents our shared commitment to flexibility, innovation, and giving people with diabetes more ways to personalize their care.upper arm and streams glucose readings minute-by-minute to twiist so you can know your glucose anytime^# with a quick glance.

Coming Early 2026

Complete the form below to stay updated on the partnership between twiist and Eversense 365 and to receive updates when it becomes available.

In the meantime, if you would like to get set up with Eversense 365 before integration launches, visit EversenseCGM.com for more information.

Keep Me in the Loop

Let's keep a good thing going! Stay connected with updates, info, and more from twiist.

*All fields required, including check boxes.

First Name:

Last Name:

Email Address:

Phone:

ZIP Code:

By checking this box, I authorize Sequel Med Tech LLC and its service providers to contact me at the number I entered above via phone and/or text (SMS) using automated dialing technology for marketing and advertising purposes. Not a condition for purchase. Message and data rates may apply. To opt-out at any time reply “STOP.”

By clicking the “Sign Up Now!” button, you confirm that you have read, understood, and agree to be bound  by Sequel Med Tech’s Terms of Use and that you have read and acknowledged Sequel Med Tech’s Privacy Policy. These Terms of Use govern your access to and use of our services, including any content, functionality, and services offered on or through our sites. If you do not agree to these terms, you must not access or use  the platform.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

References

12. Alva, S et al. "Accuracy of a 15-day Factory-Calibrated Continuous Glucose Monitoring System With Improved Sensor Design." Journal of Diabetes Science and Technology (2025): https://doi.org/10.1177/19322968251329364.

13. FreeStyle Libre 3 User’s Manual.

14. Data on file, Abbott Diabetes Care.

^§Based on a comparison of list prices of the FreeStyle Libre 3 Plus sensor versus competitors’ prescription CGM systems, assuming annual use of one receiver (or equivalent hardware) and quantity of transmitters and/or sensors according to use life. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.

^¶Among patient-applied sensors.

^#60-minute warm-up required when starting the sensor.

ADC-123320 v2.0

The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more. Refer to the manufacturers’ user guides for more information. For Eversense 365 safety information, see bit.ly/eversensesafety.

Eversense, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated.

INDICATIONS FOR USE

The twiist system is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin, ages six and above. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The twiist system is intended for single patient, home use and requires a prescription.

The twiist Loop algorithm is intended for use with compatible integrated continuous glucose monitors (iCGM) and the twiist alternate controller enabled (ACE) insulin infusion pump to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also recommend, and with the user’s confirmation, control the delivery of correction boluses when glucose values are predicted to exceed user configurable thresholds. The twiist Loop algorithm is intended for the management of type 1 diabetes mellitus in persons six years of age and greater. The twiist Loop algorithm is intended for single-patient use and requires a prescription.

The twiist Automated Insulin Delivery System includes a simple bolus calculator available when Loop is off. It is indicated for use for aiding the user in determining the bolus insulin dosage for management of diabetes mellitus based on consumed carbohydrates, operator entered blood glucose, insulin sensitivity, insulin to carbohydrate ratio, target glucose values, and current insulin on board.

CONTRAINDICATIONS

The twiist AID System is not intended for anyone unable or unwilling to:

Test blood glucose (BG) levels as recommended by their healthcare provider
Maintain sufficient diabetes self-care skills.
See their healthcare provider regularly
Demonstrate adequate carbohydrate-counting skills (preferred, not required).

The user must not:

Have difficulty seeing
Have difficulty hearing
Have deficient cognitive capabilities
Have physical impairments that would make operating the pump or iPhone difficult

Product not yet available outside of the U.S.

REFERENCES

1. Sequel Med Tech - twiist Automated Insulin Delivery (AID) System Powered by Tidepool User Guide.
2. Calculation based on a comparison of the following IFUs. The following reported 1 U/hr basal rate: Sequel Med Tech - twiist Automated Insulin Delivery (AID) System Powered by Tidepool User Guide; lnsulet - Omnipod 5 Automated Insulin Delivery System User Guide; Medtronic - MiniMed 780G system User Guide; Beta Bionics - iLet Bionic Pancreas System User Guide. The following reported 2 U/hr basal rate: Tandem Diabetes Care - t:slim X2 Insulin Pump User Guide; Tandem Diabetes Care - Tandem Mobi System User Guide.
3. lnsulet - Omnipod 5 Automated Insulin Delivery System User Guide.
4. Medtronic - MiniMed 780G system User Guide.
5. Beta Bionics - iLet Bionic Pancreas System User Guide.
6. Tandem Diabetes Care - t:slim X2 Insulin Pump User Guide.
7. Tandem Diabetes Care - Tandem Mobi System User Guide.
8. Lum JW, et al. A Real-World Prospective Study of the Safety and Effectiveness of the Loop Open Source Automated Insulin Delivery System. Diabetes Technol Ther. 2021;23(5):367-375.
9. Klonoff DC, et al. Time to Moderate and Severe Hyperglycemia and Ketonemia Following an Insulin Pump Occlusion. J Diabetes Sci Technol. 2024;18(6):1472-1479.
10. Wong JJ, et al. Psychosocial Effects of the Loop Open-Source Automated Insulin Delivery System. J Diabetes Sci Technol. 2023;17(6):1440-1447.
11. Butterfield RD, et al. Performance of a Continuous Subcutaneous Insulin Infusion (CSII) Pump With Acoustic Volume and Flow Sensing in Simulated High-Consequence Situations. IEEE Open J Eng Med Biol. 2024;5:593-599.

*The twiist™ Savings Program is available to individuals with a valid prescription and commercial insurance that covers twiist. Eligible participants can receive a Starter Kit for $0 and pay no more than $50 for Refill Kits. This offer is not valid for individuals enrolled in Medicare, Medicaid, or any other federal or state programs, or for cash-paying patients and non-covered claims. It is available only in the U.S. and is not valid in Puerto Rico, U.S. Territories, or where prohibited by law. While most commercially insured participants qualify for the $50 Refill Kit offer, those with high-deductible plans who haven't met their deductible may pay more than $50 per Refill Kit until their deductible is met. The maximum benefit is $200 per Refill Kit for covered claims. Terms are subject to change. Call us at 1-877-489-4478 or contact your insurance provider to confirm coverage.  

^†Sequel is working on adhesive options for on-body wear. Alternative adhesive options are available through third-party providers.

^‡Results obtained with the Loop algorithm using a non-twiist device.

Product for prescription only, for Important Safety Information please visit FreeStyleLibre.us
‍
The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission.

“twiist,” “iiSure,” and the twiist logo are licensed trademarks of Sequel Med Tech, LLC. “Tidepool” and the Tidepool logo are trademarks of Tidepool Project, a fully-qualified 501(c)(3) nonprofit organization.
© 2026 Sequel Med Tech, LLC. All rights reserved.